MedTrace Logo

Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan

NCT03348046 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2020-03-04

No results posted yet for this study

Summary

The purpose of this observational study is to assess the safety and effectiveness of biosimilar Infliximab in patients with rheumatoid arthritis(RA) in Jordan where no visits or intervention(s) additional to the daily practice will be performed

Conditions

Interventions

DRUG

Biosimilar Infliximab

A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • Hikma Pharmaceuticals LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-23
Primary Completion
2019-04-14
Completion
2019-04-14

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03348046 on ClinicalTrials.gov